Dendreon to Host Conference Call on February 25 to Announce Fourth Quarter and Full Year 2012 Financial Results and Webcast Presentations at Upcoming Conferences

Wed Jan 30, 2013 8:30am EST

* Reuters is not responsible for the content in this press release.

SEATTLE--(Business Wire)--
Dendreon Corporation (Nasdaq: DNDN) today announced that management will host a
conference call on Monday, February 25, 2012, at 9:00 a.m. ET to review fourth
quarter and full year 2012 financial results. 

Access to the discussion may be obtained as follows:

 Time:       9:00 a.m. ET / 6:00 a.m. PT                                   
 Date:       February 25, 2013                                             
 Dial-in:    1-877-548-9590 (domestic) or +1-720-545-0037 (international)  
             conference ID number: 95297228                                
 Webcast: (homepage and investor relations section)    

A recorded rebroadcast will be available for interested parties unable to
participate in the live conference call by dialing 1-800-585-8367 or
+1-404-537-3406 for international callers; the conference ID number is 95297228.
The replay will be available from 12:00 p.m. ET on Monday, February 25, until
11:59 p.m. ET on Monday, March 4. In addition, the webcast will be archived for
on-demand listening for 90 days at 

Dendreon Corporation also announced that management will present at the
following conferences:

* Leerink Swann Global Healthcare Conference in New York City, on February 13,
2013, at 1:30 p.m. ET 
* RBC Healthcare Conference in New York City, on February 27, 2013, at 8:30 a.m.
* Cowen and Company Healthcare Conference in Boston, on March 5, 2013, at 10:40
a.m. ET 
* Barclays Capital Global Healthcare Conference in Miami, on March 13, 2013 at
1:30 p.m. ET

The presentations will be audio webcast live and available for replay from
Dendreon's website, If you are unable to listen to the live
webcasts, they will be archived on the site following the presentation. To
access the replays, go to the Investor Relations section of the website. 

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target
cancer and transform lives through the discovery, development, commercialization
and manufacturing of novel therapeutics. The Company applies its expertise in
antigen identification, engineering and cell processing to produce active
cellular immunotherapy (ACI) product candidates designed to stimulate an immune
response in a variety of tumor types. Dendreon's first product, PROVENGE®
(sipuleucel-T), was approved by the U.S. Food and Drug Administration (FDA) in
April 2010. Dendreon is exploring the application of additional ACI product
candidates and small molecules for the potential treatment of a variety of
cancers. The Company is headquartered in Seattle, Washington and is traded on
the NASDAQ Global Market under the symbol DNDN. For more information about the
Company and its programs, visit

Dendreon Corporation
Corporate Communications
Lindsay Rocco, 862-596-1304
Joele Frank, Wilkinson Brimmer Katcher
Investor Relations
Andrea Rose, 212-355-4449

Copyright Business Wire 2013